Literature DB >> 26795458

Homeostatic cytokines in immune reconstitution and graft-versus-host disease.

Stéphanie Thiant1, Moutuaata M Moutuou1, Dominique Leboeuf2, Martin Guimond3.   

Abstract

For numerous patients, allogeneic stem cell transplantation (SCT) is the only therapeutic option that could potentially cure their disease. Despite significant progress made in clinical management of allogeneic SCT, acute graft-versus-host disease (aGVHD) remains the second cause of death after disease recurrence. aGVHD is highly immunosuppressive and the adverse effect of allogeneic SCT on T cell regeneration is typically more important than the levels of immunosuppression normally seen after autologous SCT. In these patients, immune reconstitution often takes several years to occur and restoring immunocompetence after allogeneic SCT represents an important challenge, principally because clinical options are limited and current methods used to accelerate immune reconstitution are associated with increased GVHD. Interleukin-7 and IL-15 are both under clinical investigation and demonstrate the greatest potential on peripheral T cells regeneration in mice and humans. However, awareness has been raised about the use of IL-7 and IL-15 after allogeneic SCT with regards to potential adverse effects on aGVHD. In this review, we will discuss about recent progress made in lymphocyte regeneration, the critical role played by IL-7 and IL-15 in T cell homeostasis and how these cytokines could be used to improve immune reconstitution after allogeneic SCT.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Allogeneic; CD4; CD8; GVHD; Homeostasis; IL-15; IL-7; Lymphocytes; Lymphopenia; Stromal-derived factor-1α

Mesh:

Substances:

Year:  2016        PMID: 26795458     DOI: 10.1016/j.cyto.2016.01.003

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  9 in total

1.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.

Authors:  Lindsay M Morton; Wael Saber; K Scott Baker; A John Barrett; Smita Bhatia; Eric A Engels; Shahinaz M Gadalla; David E Kleiner; Steven Pavletic; Linda J Burns
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-12       Impact factor: 5.742

2.  Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD.

Authors:  Eleonora Latis; David Michonneau; Claire Leloup; Hugo Varet; Régis Peffault de Latour; Elisabetta Bianchi; Gérard Socié; Lars Rogge
Journal:  Blood Adv       Date:  2020-08-25

3.  Cytokine and human leukocyte antigen (HLA) profile for graft-versus-host disease (GVHD) after organ transplantation.

Authors:  Xinhua Chen; Xueqin Meng; Yuning Xu; Haiyang Xie; Shengyong Yin; Hongchun Li; Liming Wu; Shusen Zheng
Journal:  Eur J Med Res       Date:  2016-10-12       Impact factor: 2.175

4.  Targeting Cytokines in GVHD Therapy.

Authors:  Sandeep Kumar; Hemn Mohammadpour; Xuefang Cao
Journal:  J Immunol Res Ther       Date:  2017-06-28

5.  Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients.

Authors:  S Thiant; M M Moutuou; P Laflamme; R Sidi Boumedine; D M Leboeuf; L Busque; J Roy; M Guimond
Journal:  Blood Cancer J       Date:  2017-04-07       Impact factor: 11.037

Review 6.  Concise Review: Boosting T-Cell Reconstitution Following Allogeneic Transplantation-Current Concepts and Future Perspectives.

Authors:  Laura Simons; Marina Cavazzana; Isabelle André
Journal:  Stem Cells Transl Med       Date:  2019-03-18       Impact factor: 6.940

Review 7.  Immune Reconstitution After Allogeneic Haematopoietic Cell Transplantation: From Observational Studies to Targeted Interventions.

Authors:  Asaf Yanir; Ansgar Schulz; Anita Lawitschka; Stefan Nierkens; Matthias Eyrich
Journal:  Front Pediatr       Date:  2022-01-11       Impact factor: 3.418

Review 8.  Restoring T Cell Homeostasis After Allogeneic Stem Cell Transplantation; Principal Limitations and Future Challenges.

Authors:  Moutuaata M Moutuou; Gabriel Pagé; Intesar Zaid; Sylvie Lesage; Martin Guimond
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

Review 9.  Evaluating Thymic Function After Human Hematopoietic Stem Cell Transplantation in the Personalized Medicine Era.

Authors:  Ahmed Gaballa; Emmanuel Clave; Michael Uhlin; Antoine Toubert; Lucas C M Arruda
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.